Clinical efficacy and safety of a pharmacopial polyherbal Unani formulation in pityriasis versicolor: a comparative

Azad Hussain Lone1, Tanzeel Ahmad, Mohd Anwar

  • 1Department of Medicine and Dermatology, National Institute of Unani Medicine (NIUM), Bangalore, India. drazadnium@rediffmail.com

Abstract

Insights

A topical polyherbal Unani formulation effectively managed pityriasis versicolor (PV), a common fungal skin infection. This treatment demonstrated superior efficacy and a quicker response compared to the standard therapy, with no observed side-effects.

Area of Science:

  • Dermatology
  • Mycology
  • Integrative Medicine
  • Pharmacology

Background:

  • Pityriasis versicolor (PV) is a superficial fungal infection caused by Malassezia furfur, presenting as scaling plaques.
  • PV commonly affects adolescents and can be challenging to treat.
  • Traditional Unani medicine utilizes various herbal remedies for PV management.

Purpose of the Study:

  • To scientifically evaluate the safety and efficacy of a topical polyherbal Unani formulation for pityriasis versicolor.
  • To compare the formulation's effectiveness against a standard treatment.

Main Methods:

  • A randomized, single-blind, standard-controlled study involving 46 patients with PV.
  • Patients received either the polyherbal formulation (test group) or 20% sodium thiosulphate lotion (control group) for one month.
  • Treatment efficacy was assessed using the Total Sign and Symptom Score (TSSS).

Main Results:

  • Both treatments significantly reduced TSSS scores (p<0.001).
  • The polyherbal Unani formulation showed a statistically significant quicker response compared to the standard drug.
  • No adverse side-effects were reported with the polyherbal formulation.

Conclusions:

  • The topical polyherbal Unani formulation is a safe and effective treatment for pityriasis versicolor.
  • The formulation demonstrated superiority over the standard treatment in terms of response speed.
  • This study supports the scientific validation of Unani herbal formulations in dermatology.

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...